Every 10-Q that Tg Therapeutics Inc (TGTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TGTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TGTX filings page.
TG Therapeutics, a commercial-stage biotech focused on B‑cell diseases, generated total revenue of $240.3 million for the quarter and $445.3 million for the first half of 2026, compared with $141.1 million and $262.0 million a year earlier, driven mainly by U.S. and ex‑U.S. sales of BRIUMVI for relapsing multiple sclerosis and related license and milestone revenue. Net income was $7.8 million for the quarter and $27.6 million year‑to‑date, with diluted EPS of $0.05 and $0.17, respectively.
Total assets reached about $1.64 billion, including $612.3 million in cash, cash equivalents and investment securities (excluding equity investments), while total liabilities were about $1.04 billion, reflecting a new $750 million term loan and repayment of a prior facility, which also produced a $9.2 million loss on extinguishment of debt. Management states it recently achieved profitability, expects existing liquidity and projected revenues to fund operations for more than twelve months, and does not currently expect to raise additional capital, though it may seek financing for strategic initiatives. The company highlights extensive risks around BRIUMVI’s market acceptance and regulation, dependence on partners and suppliers, high R&D and commercialization spending, significant stock‑based compensation, debt obligations and stock‑price volatility.
TG Therapeutics reported strong growth and continued profitability for the quarter ended March 31, 2026. Total revenue reached $204.9 million, up from $120.9 million a year earlier, driven mainly by BRIUMVI sales of $201.3 million, including $194.8 million in the U.S. and $6.5 million to ex-U.S. partner Neuraxpharm.
Net income rose to $19.8 million from $5.1 million, with diluted earnings per share of $0.12. The company ended the quarter with $572.8 million in cash, cash equivalents and investment securities and estimates these resources, together with projected revenues, will fund operations for more than twelve months.
TG Therapeutics refinanced its prior $250 million term loan with a new $750 million term loan maturing in 2031, recognizing a $9.2 million loss on extinguishment of debt. It also continued its share repurchase activity, holding 6.9 million shares in treasury at a cost of about $200.2 million.
TG Therapeutics reported Q3 2025 results highlighted by strong BRIUMVI sales and a large tax benefit. Total revenue was $161.7M, driven by product revenue of $159.3M. Operating income reached $29.4M, and net income was $390.9M, reflecting an income tax benefit of $365.0M. Diluted EPS was $2.43.
For the first nine months, total revenue was $423.7M, including $417.8M of product revenue, with $6.4M from BRIUMVI sales to Neuraxpharm. Accounts receivable were $265.4M and inventories $147.0M as of Sep 30, 2025. Cash, cash equivalents and investment securities totaled $178.3M, while loan payable (non‑current) was $245.3M.
The company completed its $100M share repurchase program, buying 2,782,545 shares for $78.2M in Q3, and authorized a new $100M program. There were 158,759,451 common shares outstanding as of Oct 31, 2025.
TG Therapeutics reported strong year-over-year commercial progress driven by BRIUMVI sales and improved profitability. For the six months ended June 30, 2025 the company recognized $262.0 million of total revenue, primarily product revenue from U.S. BRIUMVI sales, compared with $136.9 million in the prior-year period. GAAP net income was $33.2 million for the six months and $28.2 million for the quarter, reversing prior-year losses.
The balance sheet shows current assets of $663.96 million including cash, cash equivalents and investment securities the company states as $278.9 million available with management anticipating liquidity for more than twelve months. Working capital increased: accounts receivable rose to $231.5 million and inventory to $155.2 million. The company has a secured term loan with a carrying amount of $245.0 million (non-current) and an accumulated deficit of approximately $1.5 billion. Results reflect ongoing commercialization of BRIUMVI and related license revenue from ex-U.S. partner Neuraxpharm.